Shopping Cart (0)
My Account

Your Shopping Cart
International Bioprinting CongressMetabomeeting 2014Drug Discovery India 2014Enabling Genomic Technologies and Screening Asia 2014Drug Metabolism & Discovery ADMET20% Discount OfferePoster Award PrizeBlogs

Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report

Publisher: Select Biosciences
Published: January 2011
Pages: 139

Price:



This market report from Select Biosciences presents a comprehensive industry analysis of the cancer vaccines space as well as that of the emerging circulating tumor cells (CTCs) space. These two areas are evolving and expanding driven by the greater emphasis on personalized medicine especially in the cancer/oncology space.

Cancer vaccines can be generated using a number of different approaches and this report describes these approaches vis-à-vis their advantages and disadvantages and associated technical characteristics. Indeed, the FDA-approval of a cancer vaccine for prostate cancer in 2010 was a key milestone in this space and a driver for R&D efforts forward. This report presents the pre-clinical pipeline, early-stage clinical trial pipeline, and the late-stage clinical pipeline for the cancer vaccines space. Also presented are the failed vaccine candidates with a discussion about these failures and how the industry can benefit via a deeper understanding of what components are required for effective immune system activation in vivo and effective vaccination—either preventative or therapeutic.

This report also examines the technology and market landscape for circulating tumor cells (CTCs). There is currently much interest in CTCs as they may offer a highly-sensitive biomarker for cancer detection via a minimally-invasive route. The cancer research field is currently seeking to understand the role of CTCs in metastases and in this vein this report is highly-useful in that it frames the biology of CTCs, characteristics of CTCs, methodologies for CTC enrichment, CTC detection, and analytical methods. This report also snapshots the clinical trials being conducted currently involving CTCs.

Extensive Worldwide Technical and Market Analyses Presented in this Report:

  • Classification and Characterization of Cancer Vaccines
  • Various Approaches for the Generation of Cancer Vaccines
  • Anti-Cancer Vaccination Strategies
  • Tumor Associated Antigens (TAAs)
  • Tumor Specific Antigens (TSAs)
  • Failed Anti-Cancer Vaccine Candidates and Reasons for such Failure
  • Strategies to Improve Success of Cancer Vaccines
  • US FDA-Approved Cancer Vaccines
  • Therapeutic Cancer Vaccines Approved in Various Countries Around the World
  • Cancer Vaccine Pipeline in Late-Stage Clinical Trials
  • Cancer Vaccine Pipeline in Early-Stage Clinical Trials
  • Pre-Clinical Cancer Vaccine Pipeline
  • Personalized Cancer Vaccination Strategies
  • Biology and Characteristics of CTCs
  • Methodologies/Various Technologies for Enrichment, Detection, and Characterization of CTCs
  • More details of the scope of coverage of this industry report are found in the Table of Contents (TOC) for the report—see below for link to downloadable PDF of the TOC

Report Table of Contents (TOC) [Click Here to Download PDF File]


For enquiries about this market report, please contact Kathy Gray at Kathy.Gray@Selectbiosciences.com

Conference News
Site Visit to the SIMTech Microfluidics Foundry
Site Visit to the SIMTech Microfluidics Foundry
Take advantage of a tour of the facilities at the SIMTech Microfluidic Foundry. Dr. Zhiping Wang, Director of Research Programmes, will be your host, providing all attendees with a detailed insight into the advanced work carried out by SIMTech. Don't miss out - Register today!


The International Bioprinting Congress - Tour of facilities at the NTU Additive Manufacturing Centre
The International Bioprinting Congress - Tour of facilities at the NTU Additive Manufacturing Centre
An opportunity not to be missed. Take advantage of a free tour of the new NTU Additive Manufacturing Centre (NAMC). Supported by Singapore’s Economic Development Board (EDB), the NAMC will have the latest 3D printing machines, including bioprinters which are able to print human tissues. The centre opens officially in May 2014, so you will be one of the first to have an official guided tour with the Director of the Facility, Professor Chua Chee Kai.


LAB-ON-A-CHIP ASIA - EARLY BIRD
SAVE UP TO S$ 255 - EARLY BIRD DEADLINE 10 OCTOBER 2014!


Agenda now on-line - Enabling Genomic Technologies and Screening Asia 2014
Agenda now on-line - Enabling Genomic Technologies and Screening Asia 2014
The agenda for Enabling Genomic Technologies and Screening Asia 2014 is now on-line. Don't miss out on our Early Bird Pricing - Register Today!


Papers Presented in Enabling Genomic Technologies & Screening Asia can be Published in CSBJ
Papers Presented in Enabling Genomic Technologies & Screening Asia can be Published in CSBJ
Computational and Structural Biotechnology Journal [CSBJ (ISSN 2001-0370)] will devote a conference special issue comprising of selected articles from the speakers/oral and poster presenters of Enabling Genomic Technologies & Screening Asia conference. Selected authors will receive an invitation to submit full length manuscripts to CSBJ. The full length manuscripts will undergo the peer-review process as per CSBJ policies. From July-2014, CSBJ will be part of ELSEVIER Open-access Journals.


Papers Presented in the Lab-on-a-Chip Asia- Microfluidics * Point-of-Care Diagnostics conference can be Published in CSBJ
Papers Presented in the Lab-on-a-Chip Asia- Microfluidics * Point-of-Care Diagnostics conference can be Published in CSBJ
Computational and Structural Biotechnology Journal [CSBJ (ISSN 2001-0370)] will devote a conference special issue comprising of selected articles from the speakers/oral and poster presenters of Lab-on-a-Chip Asia- Microfluidics * Point-of-Care Diagnostics conference. Selected authors will receive an invitation to submit full length manuscripts to CSBJ. The full length manuscripts will undergo the peer-review process as per CSBJ policies. From July-2014, CSBJ will be part of ELSEVIER Open-access

Scroll Up
Scroll Down
Keep me updated Select Bio Blog LinkedIn Twitter LabTube.tv SBOnDemand.com MarketReports.com Research-Store.com